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The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and
serum/plasma. It is important to test these recommended protocols on nonsimulated “in vivo” specimens before full clinical
evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides
experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended proto-
cols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript
describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea
pig model of IA were used for WB and serum PCR. Galactomannan and -D-glucan detection were evaluated, with particular
focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum
PCR, galactomannan, and -D-glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%,
79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and -D-glucan val-
ues were indicators of disease progression. The combination of WB PCR with galactomannan and -D-glucan proved optimal
(area under the curve [AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols
provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA
can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be bal-
anced against the practicality and cost of using multiple tests.
The diagnosis of invasive aspergillosis (IA) remains difficult,resulting in the widespread use of empirical therapy or po-
saconazole prophylaxis in high-risk patients. Definitive (proven)
diagnosis of IA requires microscopic evidence of invasive fungal
disease in tissue and/or culture ofAspergillus sp. from the diseased
area (1). Most patients are diagnosed with probable or possible IA
based on specific radiological signs with or without the detection
of biomarkers (galactomannan [GM] or -D-glucan [BDG]) or
culture of Aspergillus (1).
Direct detection of Aspergillus in clinical specimens using mo-
lecular methods is yet to be included in criteria for defining inva-
sive fungal disease (IFD), which is a result of limited standardiza-
tion (1). The European Aspergillus PCR Initiative (EAPCRI)
provided recommendations based on simulated samples to stan-
dardize procedures for whole blood (WB) and serum/plasma (2,
3). Following evaluation of analytical performance but before
widespread multicenter clinical evaluation, it is important that
these recommended protocols are used to test “nonsimulated”
specimens to determine performance when detecting targets gen-
erated in vivo. Animal models have been used to evaluate the di-
agnosis and treatment of IA (4, 5). Animal models can overcome
the relatively low incidence of disease and allow the application of
experimental design and control, which is not possible in the clin-
ical setting. Testing an animal model would support the initial
clinical validation, and inadequate performance at this stage
would highlight limitations that were necessary to overcome be-
fore large-scale clinical trials are performed (6–8).
In order to continue with the PCR standardization process, the
EAPCRI formed an international collaboration with the NIH-
founded Invasive Aspergillosis Animal Models (IAAM) group to
evaluate the performance of theAspergillus PCR protocols recom-
mended by the EAPCRI when testing blood samples derived from
a guinea pig model of IA. In addition to the performance of PCR,
the detection of other circulating biomarkers, galactomannan
(GM) and -D-glucan (BDG), was also evaluated with particular
focus given to the timing of positivity and the concept of combi-
nation testing, and the findings are described.
MATERIALS AND METHODS
Animal model of invasive aspergillosis. Prior to inoculation with Asper-
gillus conidia, 43 male Hartley guinea pigs (Charles River Laboratory,
Wilmington, MA) were immunosuppressed using intraperitoneal cyclo-
phosphamide (Cytoxan; Mead Johnson, Princeton, NJ) and subcutane-
ous cortisone acetate (Sigma, St. Louis, MO) as previously described (4).
In addition, animals received daily antibiotic prophylaxis with ceftazi-
dime (50 mg/kg of body weight; GSK Beecham Pharmaceuticals, Phila-
delphia, PA) to prevent bacterial infection. All procedures were approved
by the Institutional Animal Care and Use Committee at the University of
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Texas Health Science Center at San Antonio, and animals were main-
tained in accordance with the Association for the Assessment and Accred-
itation of Laboratory Animal Care (9).
On the day of inoculation, 30 immunosuppressed animals were placed
individually in an acrylic chamber to permit inoculation with a nebulized
suspension of Aspergillus fumigatus AF293 conidia (7  107 conidia/ml)
for 1 h with a flow rate of 100 kPa. Confirmation of the conidial delivery
was accomplished by humanely killing one guinea pig to allow enumera-
tion of the lung conidial load, which after 1 h of inoculation was 3.8 104
CFU/g tissue. One hour, 5 days, 7 days, and 9 days after inoculation,
infected animals (4, 13, 9, and 4, respectively, at each time point) were
humanely killed, and whole blood samples were drawn by cardiac punc-
ture. An additional 13 immunosuppressed animals served as uninfected
controls that were potentially vulnerable to IA, and a further 13 immuno-
competent animals served as uninfected IA invulnerable control animals.
Control animals were euthanized at the corresponding time points, and
disease was confirmed in a postmortem investigation of lung tissue (10).
Throughout the study, animals were monitored daily for any obvious
signs of illness or other signs of distress. Any animal found to bemoribund
before the end of the study was euthanized.
In keeping with EAPCRI recommendations, 3 ml whole blood (WB)
(3 ml) was collected into EDTA Vacutainer tubes and was rocked for 5
min before being frozen at80°C for PCR testing (2). WB without anti-
coagulant was fractionated by centrifugation, and the serum component
was removed and stored at80°C for GM, BDG, and PCR testing.
Testing strategy. GM and BDG testing was performed by the IAAM
group. The EDTA WB samples for molecular testing were divided across
four experienced EAPCRI centers (Public Health Wales Microbiology
Cardiff; Radboud Medical Centre, Nijmegen; St. Louis Hospital, Paris;
and University Hospital Wuerzburg). Serum samples were tested by one
EAPCRI center (Public HealthWales Microbiology Cardiff). All methods
were compliant with recommendations for the testing of serum andWB,
providing optimal analytical performance (2, 3).
GM testing. The Bio-Rad Platelia Aspergillus enzyme immunoassay
(EIA) kit was used to detect galactomannan using 300l of serum follow-
ing manufacturer’s instructions and a positivity index of 0.5.
BDG testing. BDG testingwas performed using the Associates of Cape
Cod Fungitell assay using 5 l of serum and a positivity threshold of 80
pg/ml. Samples with a BDG concentration of between 60 and 79 pg/ml
were considered indeterminate, and samples below 60 pg/ml were consid-
ered negative. The test was performed according to the manufacturer’s
instructions.
Serum DNA extraction. DNA was extracted from 0.5 ml of serum
using theHigh Pure template DNAkit (Roche, BurgessHill, United King-
dom). All DNA was eluted in 60 l and generated excellent analytical
performance when previously evaluated (3). Positive (healthy donor se-
rum spikedwithA. fumigatus genomicDNA) andnegative (healthy donor
serum) extraction controls were used tomonitor extraction performance.
Whole blood DNA extraction. DNA was extracted from 3.0 ml of
EDTA WB using the standard EAPCRI protocol as previously described;
however, when erythrocytes persisted after 2 cycles of red cell lysis, an
additional red cell lysis step was performed (2). After bead beating, two
EAPCRI centers (Nijmegen and Paris) used the MagNA Pure LC large
volume kit (Roche) and two centers (Wuerzburg and Cardiff) used the
High Pure template DNA kit (Roche) for final DNA purification and
elution. All DNA was eluted at a volume of 100 l. The two methods
generate excellent analytical performance as described previously (2).
Positive extraction controls (healthy donor EDTA WB spiked with A.
fumigatus conidia) and negative extraction controls (healthy donor EDTA
WB) were included to monitor extraction performance.
PCR amplification. The EAPCRI centers performed Aspergillus-spe-
cific real-time PCR targeting the 28S rRNA unit (Cardiff and Nijmegen),
the internal transcribed spacer 2 (ITS 2) region (Wuerzburg), and a com-
bined approach using two PCRs targeting rRNA/mitochondrial DNA re-
gions (Paris) (7, 11, 12). All methods have shown excellent analytical
performance (2, 3). An internal control PCR was performed to monitor
for inhibition as recommended (2, 3). All PCR testing was performed in
duplicate, and, where possible, a third replicate was tested to resolve dis-
crepant results.
Statistical analysis. To determine the clinical performances (sensitiv-
ity, specificity, likelihood ratios, overall accuracy, and diagnostic odds
ratio) of the assays, 2 by 2 tables were constructed using the infected
animals as true cases and uninfected animals as a control population. For
all animals, only a single sample was tested by each assay; consequently,
only a single positive was required to consider the animal positive by a
specific test. For PCR testing, only individual samples thatwere confirmed
by repeat testing (2/2 or 2/3 replicates positive) were considered PCR
positive. For the proportionate values of the individual assays, 95% con-
fidence intervals (95%CIs) and,when required for comparative purposes,
P values (Fisher’s exact test; P  0.05) were generated to determine the
significance of the differences between rates (13). For the individual quan-
titative assays (BDG and GM) and for combined assay strategies, receiver
operator characteristic (ROC) curve analysis was performed, and the area
under the curve (AUC) was calculated using GraphPad Prism 5 (Graph-
Pad Software, La Jolla, CA, USA). For the ROC analysis of the combina-
tion of assays, the threshold used to determine positivity related to the
number of positive assays required before confirming IA was explored.
RESULTS
A total of four different assays were performed (GM and BDG on
serum samples only and PCR testing of serum and whole blood)
on the samples taken from the animal model. The individual per-
formance of each assay is shown in Table 1.
BDG performance. Using the manufacturer’s positivity
threshold of 80 pg/ml, BDG testing generated excellent specificity,
but sensitivity was compromised compared to the other assays
(Table 1). The specificity of the BDG assay was significantly supe-
rior to that of serumPCR (P 0.0223) andGM testing (P 0.05).
ROC analysis showed that to attain sensitivity comparable to the
other assays used in this study, the threshold would need to be
reduced to 42.73 pg/ml providing sensitivity and specificity values
of 63.6% (95%CI, 40.7% to 82.8%) and 92.0% (95%CI, 74.0% to
99.0%), respectively (Fig. 1a). The highest sensitivity (54.6%)
while maintaining a specificity of 100% was achieved using a
threshold of 58.63 pg/ml. Positivity in infected animals was first
seen on day 5 at a positivity rate of 45.5%, and this increased to
60% and 100% on days 7 and 9, respectively (Fig. 2). On day 7, no
animals were negative by BDG testing, but two animals were
deemed indeterminate generating BDG concentrations of 61.1
and 66.4 pg/ml. The concentration of BDG detected in the serum
of infected animals increased during the course of the experiment,
with a day 1mean value of31.25 pg/ml and rising to 70.0, 333.1,
and 742.9 pg/ml on days 5, 7, and 9, respectively (Fig. 3a). The
mean concentration of BDG in the serum of uninfected animals
over the course of the experiment was31.25 pg/ml.
Galactomannan performance. ROC analysis confirmed that
optimal performance was attained using an index of 0.5, although
100% sensitivity or 100% specificity was only achieved using in-
dices of 0.1 and 2.2, respectively, with obvious deleterious effects
on diagnostic performance (Fig. 1b). Again, positivity in infected
animals was first seen on day 5 at a positivity of 81.8% increasing
to 100%byday 9 (Fig. 2a).Unlike BDG testing,GM false positivity
was detected throughout the course of the study (rate, 12.5% to
40.0%) (Fig. 2b). Increasing the positivity index to 0.8 reduced the
false positives by 80% and generated sensitivity and specificity
values of 50.0% and 96.0%, respectively. As with BDG, GM indi-
ces increased during the experiment, with a day 1 mean index of
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0.3 rising to 1.1, 4.4, and 9.8 on days 5, 7, and 9, respectively (Fig.
3a). The mean index in the serum of uninfected animals over the
course of the experiment was 0.4.
PCR performance. Overall sensitivity was comparable be-
tween the PCR assays and GM testing, although there was a trend
toward increased WB PCR sensitivity compared to that of BDG
(P  0.0765) (Table 1). Unlike antigen testing, PCR assays were
able to detect Aspergillus biomarkers inWB and serum on the day
of inoculation, with a slight reduction in positivity on day 5 before
increasing during the latter stages of the experiment (Fig. 2a). PCR
false positivity was comparable with that for GM EIA (Fig. 2b).
Unlike GM and BDG testing, there did not appear to be an in-
crease in available target as disease progressed, and for serum and
WBPCR, the relative quantification cycle (Cq) (or threshold cycle)
did not increase during the experiment (Fig. 3b). Indeed,Cq values
were similar in infected and uninfected animals (for WB PCR,
35.7 versus 36.8 cycles), although the frequency of PCR positivity
was significantly greater in infected animals. For WB PCR, the
difference in PCR positivity rates across the duration of the study
in infected compared to the false positivity rate in uninfected an-
imals was 51.8% (P 0.0001), and for serum PCR the difference
was 46.0% (P 0.0001).
Combination testing. In this study, BDG testing alone pro-
vided 100% specificity across the duration of the study, but sensi-
tivity was compromised (45.5%) resulting in a poor likelihood
ratio for a negative test result (LR, 0.55) (Table 1). When com-
bining two biomarker assays, GM and WB PCR improved sensi-
tivity to 100% if one of the two assays was positive, representing
significant increases in sensitivity of 27% (P  0.0123) and 32%
(P 0.0089) compared to the individual use ofWBPCR andGM,
respectively. Using this dual WB PCR/GM strategy, there was no
significant reduction in specificity compared to that of individual
use of the assays (GM, P 1.00; WB PCR, P 0.23), and	95%
specificity was attained if the two assays were positive (Table 1).
No dual assay strategy was able to confidently exclude and diag-
nose IA (i.e., 100% sensitivity and specificity), and a minimum
combination of three assays was required to achieve this goal.
Combining eitherWB or serum PCRwith the two antigen tests or
TABLE 1 The diagnostic performance of individual assays compared with combination testinga
Assaysb
Sensitivity
(%)
Specificity
(%)
Accuracy
(%) LR
c LRd DORe
ROC analysis,
AUC (95% CI)
WB PCRf (95% CI) 73 (54–86) 92 (76–98) 82.7 9.5 0.3 32.7
Serum PCR (95% CI) 65 (46–81) 79 (60–91) 72.0 3.1 0.4 7.3
GM (95% CI) 68 (47–84) 80 (61–91) 74.5 3.4 0.4 8.5 0.77 (0.62–0.91)
BDG (95% CI) 46 (27–65) 100 (86–100) 74.5 	455 0.6 	827.3 0.82 (0.70–0.95)
Serum/WB PCR 91/33 65/100 77/68 2.6/	330 0.1/0.7 18.6/	495 0.84 (0.72–0.96)
BDG/WB PCR 86/24 91/100 89/64 9.6/	240 0.2/0.8 48/	300 0.90 (0.79–1.00)
GM/WB PCR 100/33 78/96 89/66 4.5/8.3 0.001/0.7 	4500/11.8 0.91 (0.81–1.00)
BDG/serum PCR 76/33 74/100 75/68 2.9/	330 0.3/0.7 9.7/	471 0.79 (0.66–0.93)
GM/serum PCR 90/43 61/96 75/70 2.3/10.8 0.2/0.6 11.5/18 0.82 (0.70–0.95)
GM/BDG 81/38 83/100 82/70 4.8/	380 0.2/0.6 24/	613 0.85 (0.73–0.97)
WB PCR/GM/BDG 100/67/14 78/96/100 89/82/59 4.5/16.8/	140 0.001/0.3/0.9 	5000/57/	156 0.95 (0.88–1.00)
Serum PCR/GM/BDG 100/48/33 61/96/100 80/73/68 2.6/12/	330 0.002/0.5/0.7 	1300/24/	471 0.88 (0.79–0.98)
WB/serum PCR/BDG 90/71/10 65/100/100 77/86/57 2.6/	710/	100 0.2/0.3/0.9 13/	2367/	111 0.90 (0.81–1.00)
WB/serum PCR/GM 100/81/14 57/91/100 77/86/59 2.3/9/	140 0.002/0.2/0.9 	187/45/	156 0.92 (0.84–1.00)
All four assays 100/91/44/10 57/91/100/100 77/91/73/57 2.3/10.4/	429/	950 0.001/0.1/0.6/0.9 	2300/104/	751/	1044 0.95 (0.90–1.00)
a For combined assay performance, the first figure represents the performance if one of the assays was required positive for the animal to be considered positive, the second figure if
two assays were required positive, and so on. For example, for combined serum/WB PCR, if one of the assays was required positive then sensitivity and specificity of 91% and 65%
were generated. If both were required positive, then sensitivity and specificity were 33% and 100%, respectively. For assays with 100% sensitivity or specificity, likelihood ratios and
diagnostic odds ratio have been calculated using a value of 99.9% and are representative values used to replace .
b GM, galactomannan Bio-Rad Aspergillus Ag test; BDG: -d-glucan Associates of Cape Cod -d-glucan test.
c LR
, likelihood ratio for a positive test result.
d LR, likelihood ratio for a negative test result.
e DOR, diagnostic odds ratio.
f Excludes one case where the sample was inhibitory to PCR amplification.
FIG 1 Receiver operator characteristic curves for -D-glucan (a) and galacto-
mannan enzyme-linked immunosorbent assay (ELISA) testing (b).
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combining the two PCR tests with GM provided performance
such that if all assays were positive an animal could be diagnosed
with IA, whereas if all assays were negative disease could be ex-
cluded (Table 1). Of the triple strategies, the WB PCR/GM/BDG
approach using a threshold of a single positive assay as significant
provided the best diagnostic accuracy (89%). It was confirmed by
ROC analysis, where the combination ofWB PCR/BDG/GMpro-
vided an AUC that was superior to the other triplet strategies and
that was comparable to the AUC generated when combining all
four assays, that the latter strategy provided no additional benefit
over using WB PCR in combination with the two antigen tests.
DISCUSSION
In this study, the performance of standardized PCR methodolo-
gies proposed by the EAPCRI for testing serum andWBwas com-
pared to that of antigen detection in an animal model of IA. BDG
testing provided excellent specificity, but sensitivity was compro-
mised until the late stages of the experiment. Unlike the clinical
scenario, the animals in this study were not exposed to the various
clinical factors associated with false-positive BDG results (14).
Consequently, the specificity of the BDG assay for the detection of
IA may be higher than that seen in the clinic and may be further
compounded by the ability to detect but not differentiate fungal
pathogens other than Aspergillus. In this model, the optimal pos-
itivity threshold was 58.6 pg/ml; however, given the limitations
stated above, in clinical practice it would be wise not to lower the
current threshold. For GM, the current positivity index of 0.5
provided optimal overall performance (sensitivity, 68.2% [95%
CI, 45.1% to 86.1%]; specificity, 84.0% [95% CI, 63.9% to
95.5%]) with an index of 1.0 generating a specificity of 96.0%
FIG 2 Galactomannan, -D-glucan, and PCR positivity for the individual time points across the time course of the experiment: (a) infected animals and (b)
uninfected animals. Galactomannan positivity was determined using a threshold index of 0.5, and -D-glucan positivity was determined using a threshold of 80
pg/ml. All PCR positives were confirmed by repeat testing.
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(95% CI, 79.7% to 99.9%) and positive likelihood ratio of 12.5,
which is sufficient to confirm disease.
Disease progression coincided with increasing levels of GM
and BDG, whereas PCR testing performed better during early
stages. Serum and WB PCR assays were uniformly positive 1 h
after inoculation of the animals, a period that precludes the dis-
ease process, as the formation of hyphae, required for invasion,
takes between 6 and 24 h to develop (15). This suggests that PCR
positivity in blood can reflect exposure and is not solely dependent
on angioinvasion. This probably represents detection of phagocy-
tosed conidia within translocated alveolar macrophages (16) and
may provide an opportunity to initiate targeted prophylaxis or
preemptive therapy to preempt disease in at-risk patients who
have had a significant exposure. Given the limited number of an-
imals tested at this time point, further testing is warranted to con-
firm the significance of this finding.
False positivity was noted for GM and the two PCR assays but
was significantly less than the corresponding true positivity rates.
Comparing the immunosuppressed control population with the
immunocompetent control population, false positivity for GM
and PCR was greater in the immunosuppressed population (dif-
ference of 15.0% [95% CI, 0.9% to 28.5%]; P 0.043). It is pos-
sible that this represented natural infection and slower clearance
of conidia inhaled from the environment. No false positivity was
noted with BDG testing, and this may simply be the result of
reduced sensitivity or because the animals had not been exposed
to agents associated with false positivity in the clinic.
The study gives new insights into the timing of biomarker re-
lease critical to their use as a test in a preemptive or diagnostic-
driven approach. GM and BDG are released during active hyphal
growth, which is indicative of progression of infection to disease
(17). Cordonnier et al. showed that a diagnostic approach based
on radiological and GM testing increased the incidence of IA di-
agnosis with no overall effect onmortality rates, although antifun-
gal usage was reduced (18). Targeting GM and BDG alone may
detect early infection in a diagnostic-driven strategy but may be
insufficient to preempt disease. In this study, PCR positivity pre-
dated antigen positivity, and this has been shown in the clinical
setting, where in one study DNAemia was detected on average 68
days before GM and in a second where PCR preceded GM in 15
patients with IA (19–21). Not all susceptible patients exposed to
Aspergillus will develop disease, and PCR will generate false-posi-
tive results with respect to IA. However, this information may be
used to direct prophylactic and preemptive strategies, particularly
in patients at increased risk of IA. In particular, PCR testing can be
combined with genetic screening of the host to determine muta-
tions in immunity, such as dectin-1, which increases susceptibil-
ity, and further support initiating preemptive therapy (22).
However, the timing of presentation of the patient is critical,
and antigen testing may prove beneficial for a symptomatic pa-
tient presenting with clinical signs typical of IA without any prior
diagnostic work-up, particularly as, in this study, antigen levels
increased during the course of the experiment. A combined diag-
nostic strategy can be used to preempt, diagnose, and monitor
disease progression, in addition to excluding disease. Millon et al.
performed real-time PCR on the first GM-positive serum, and
patients positive by PCR and GM had a poor prognosis (23). In
diagnosing the disease, this strategy is adequate; however, for
screening or preemptive strategies, it may be beneficial to reverse
this algorithm using PCR to detect possible exposure/early infec-
tion and antigen testing to monitor for disease progression. By
combining multiple biomarker tests, IA can be confidently ex-
cluded or confirmed. This result highlights the need for a diagnos-
tic strategy using combination testing to screen or, alternatively, to
confirm diagnosis. Four tests were evaluated in this study. Com-
bining either of the PCR assays with BDG and GM or both PCR
assays with GM allowed disease to be excluded or diagnosed. This
approach must be balanced against the practicality and cost of
using multiple tests. Recent clinical trials, supported by a meta-
analysis, comparing a combination approach using GM and
Aspergillus PCR with conventional methods, have shown signifi-
cant benefits, including a reduction in disease burden (24–26).
While the cost of multiple tests may seem prohibitive, it can be
more than offset by the reduction in unnecessary antifungal ther-
apy driven by the high sensitivity and negative predictive value of
combination testing (24–26). From a practical standpoint, serum/
plasma PCR and GM can be performed on the same sample and
can be automated, reducing pressure on the laboratory (27). WB
and serum PCR can be streamlined by combining serum andWB
DNA extractionmethods into a single process resulting in a single
PCR test to be combined with GM (28). Unfortunately, due to
limited sample material, it was not possible to evaluate this com-
bined approach in this study. Another limitation is that plasma
was not available, as all EDTA WB was frozen post sampling. In
human material, PCR and GM testing of plasma has been shown
to generate superior results over serum, and it would have been
beneficial if this were investigated in this study (8, 29, 30).
These results confirm satisfactory performance of the EAPCRI
FIG 3 Mean biomarker values over the course of the experiment: (a) galacto-
mannan and -D-glucan and (b) PCR detection. Values represent the mean
figure from infected and uninfected animals at that particular time.
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recommendations for PCR testing of serum andWB compared to
that of commercially available antigen tests. It is essential that the
performance of the EAPCRI recommendations is fully evaluated
in a clinical trial to determine accurate clinical performance.
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